Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence.

ABSTRACT:

Background and aims

Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clinical models in the treatment of NSCLC both alone and as part of chemotherapeutic regimens.

Methods

Five databases were searched from inception to February 2023 to identify published clinical trial data and ongoing clinical trials on the use of proteasome inhibitors in treatment of NSCLC with a comprehensive search strategy.

Results

This review examines the clinical evidence from 21 completed and published phase I and II trials studying the use of bortezomib monotherapy and combination therapy in the treatment of NSCLC. Bortezomib/d

SUBMITTER: Chua ADW 

PROVIDER: S-EPMC10643516 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature